Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
0.3090 +0.0094 (+3.14%) 10:19 ET [NASDAQ]
0.3101 x 210 0.3140 x 100
Realtime by (Cboe BZX)
0.3101 x 210 0.3140 x 100
Realtime 0.3153 +0.0157 (-) 09:29 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3000
Day High
0.3148
Open 0.3053
Previous Close 0.2996 0.2996
Volume 133,957 133,957
Avg Vol 888,714 888,714
Stochastic %K 70.62% 70.62%
Weighted Alpha -33.55 -33.55
5-Day Change +0.0098 (+3.31%) +0.0098 (+3.31%)
52-Week Range 0.1800 - 1.7400 0.1800 - 1.7400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,273
  • Shares Outstanding, K 101,044
  • Annual Sales, $ 29,620 K
  • Annual Income, $ -47,580 K
  • EBIT $ -113 M
  • EBITDA $ -112 M
  • 60-Month Beta 0.87
  • Price/Sales 0.98
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.23
  • Most Recent Earnings $-0.08 on 03/17/25
  • Next Earnings Date 05/05/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 565.57% ( -53.13%)
  • Historical Volatility 112.16%
  • IV Percentile 93%
  • IV Rank 51.32%
  • IV High 1,051.52% on 04/04/25
  • IV Low 53.20% on 08/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 51
  • Volume Avg (30-Day) 337
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 17,347
  • Open Int (30-Day) 16,383

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate 0.02
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +109.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2300 +33.04%
on 04/09/25
Period Open: 0.3150
0.3840 -20.31%
on 03/25/25
-0.0090 (-2.86%)
since 03/21/25
3-Month
0.2300 +33.04%
on 04/09/25
Period Open: 0.5062
0.8775 -65.13%
on 02/20/25
-0.2002 (-39.55%)
since 01/23/25
52-Week
0.1800 +70.00%
on 11/13/24
Period Open: 1.0700
1.7400 -82.41%
on 05/07/24
-0.7640 (-71.40%)
since 04/23/24

Most Recent Stories

More News
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FGEN : 0.3090 (+3.14%)
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

FGEN : 0.3090 (+3.14%)
FibroGen: Q4 Earnings Snapshot

FibroGen: Q4 Earnings Snapshot

FGEN : 0.3090 (+3.14%)
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FGEN : 0.3090 (+3.14%)
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

FGEN : 0.3090 (+3.14%)
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FGEN : 0.3090 (+3.14%)
FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen appoints David DeLucia as Chief Financial Officer, effective December 16, 2024, following Juan Graham's departure.Quiver AI SummaryFibroGen, Inc. has appointed David DeLucia as the new Chief Financial...

FGEN : 0.3090 (+3.14%)
FibroGen Appoints David DeLucia as Chief Financial Officer

FGEN : 0.3090 (+3.14%)
FibroGen: Q3 Earnings Snapshot

FibroGen: Q3 Earnings Snapshot

FGEN : 0.3090 (+3.14%)
FibroGen Reports Third Quarter 2024 Financial Results

FGEN : 0.3090 (+3.14%)

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 0.3205
2nd Resistance Point 0.3115
1st Resistance Point 0.3055
Last Price 0.3090
1st Support Level 0.2905
2nd Support Level 0.2815
3rd Support Level 0.2755

See More

52-Week High 1.7400
Fibonacci 61.8% 1.1441
Fibonacci 50% 0.9600
Fibonacci 38.2% 0.7759
Last Price 0.3090
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro